Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Cld seminar 2


Published on

chronic liver disease in a nut shell , tried to simplify the matter with diagrams . standard references being used for it .

Published in: Health & Medicine
  • Reasons why you should know this homemade recipe to stop your hair loss ➤➤
    Are you sure you want to  Yes  No
    Your message goes here
  • How To Cure Acne For Good, Achieve lasting acne freedom Simple proven science of clear skin ♣♣♣
    Are you sure you want to  Yes  No
    Your message goes here
  • It's been ten months without a yeast infection. More than that, for the past couple of months I only had one migraine attack, comparing to six a week as I used to. I also very often suffered from runny nose and acne on my forehead. Since I started your program, it's been like a miracle. My acne disappeared in less than 2 weeks, I lost 10 pounds, and the flu like symptoms I often use to suffer from are also a thing of the past. I feel so young and empowered and I would have never believed there was a natural solution for my problems, if I was told a year ago. I wish everybody knew about this method. There are so many hopeless women and men out there with candida yeast infections. I know I will never have to go through that again. ▲▲▲
    Are you sure you want to  Yes  No
    Your message goes here
  • I have started the program this September and I must say I'm very pleased with the results. I was overweight and sick from candida and had severe swelling, and redness in the vulva area including vaginal discharge. Using your program I have lost a TON of weight. I no longer itch and scratch. The vaginal discharge had stopped and I'm feeling better than ever. I have also found through your book that some of my other health problems are from candida yeast overgrowth. My acid reflux and my skin texture had dramatically improved and I feel awesome physically. ▲▲▲
    Are you sure you want to  Yes  No
    Your message goes here
  • I have started the program this September and I must say I'm very pleased with the results. I was overweight and sick from candida and had severe swelling, and redness in the vulva area including vaginal discharge. Using your program I have lost a TON of weight. I no longer itch and scratch. The vaginal discharge had stopped and I'm feeling better than ever. I have also found through your book that some of my other health problems are from candida yeast overgrowth. My acid reflux and my skin texture had dramatically improved and I feel awesome physically. ■■■
    Are you sure you want to  Yes  No
    Your message goes here

Cld seminar 2

  1. 1. • Definition • Pathophysiology • Aetiology of chronic liver disease • Symptoms and signs of chronic liver disease • Investigations in chronic liver disease • Treatment • Complications in chronic liver disease
  2. 2. Cirrhosis is derived from Greek word kirros=orange or tawny and osis=condition -WHO definition : it is defined as a diffuse process characterized by liver necrosis and fibrosis and conversion of normal liver architechture into structurally abnormal nodules that lack normal lobular organisation.
  3. 3. • Cirrhosis is a form of chronic liver injury that represents an end stage of virtually any progressive liver disease. • cirrhosis may be superimposed on the primary liver disease and obscure the nature of the original insult. • As cirrhosis advances, it results in distortion of liver architecture and compression of hepatic vascular and biliary structures. These critical architectural changes lead to irregular delivery of nutrients, oxygen, and metabolites to various areas of the liver and may perpetuate the cirrhotic process even after the original insult has been brought under control or has ceased .
  4. 4. It can be classified on the basis of morphology and etiology
  5. 5. • Micronodular cirrhosis : In micronodular cirrhosis the nodules are regular and small nodules and It is <3mm in diameter . There is diffuse involvement of all the hepatic lobules separated by the thick diffuse septa. In its early stages extra hepatic Billiary atresia is micronodular.
  6. 6. Micronodular cirrhosis:
  7. 7. • Macronodular cirrhosis : in this type the nodules are of various size and are generally larger than 5mm in diameter and the nodules are separated by irregular septa of varying width. • Macronodular cirrhosis is a feature of advanced Wilson’s disease, α-1 antitrypsin deficiency, chronic active hepatitis
  8. 8. Macronodular Cirrhosis
  9. 9. • Mixed cirrhosis : Some parts of the liver show micronodular appearance and some part show macronodular pattern.
  10. 10. Laennec Cirrhosis (most common 60-70%) Post necrotic cirrhosis (10%) Biliary cirrhosis (5 -10%) Cardiac cirrhosis Indian childhood cirrhosis
  11. 11. cirrhosis is characterized by bile stasis, general reduction of bile ducts, and increased amounts of connective tissue within and extending from portal tracts .  The lobular structure generally is preserved.  This pattern often is ultimately seen in children with biliary atresia, cystic fibrosis, and progressive familial intrahepatic cholestasis I.
  12. 12. Postnecrotic cirrhosis, also known as irregular cirrhosis, is the result of chronic and recurrent liver cell destruction.  It is usually not a result of a single necrotic injury and is characterized by piecemeal necrosis that occurs at the interface between hepatocytes and portal tracts or fibrous septa. Bridging fibrosis, collapsed hepatic lobules, and regenerative nodules of varying sizes develop, usually producing micronodular cirrhosis .
  13. 13. In children, postnecrotic cirrhosis may occur as a sequela of neonatal hepatitis. It is associated with chronic active hepatitis, caused by viral hepatitis B or C, or a result of autoimmune or idiopathic inflammation . Drugs such as methyldopa or isoniazid, which may cause chronic active hepatitis, also can cause irregular or postnecrotic cirrhosis .
  14. 14.  Cardiac cirrhosis develops as a result of centrilobular hemorrhagic necrosis.  Increased right atrial pressure (resulting from congestive heart failure, congenital heart disease, or constrictive pericarditis) results in increased hepatic vein pressure and congestion of blood flow in centrilobular areas.  Necrosis leads to formation of fibrous bridges between central veins.
  15. 15.  Vaso occlusive disorders and the Budd–Chiari syndrome, which results from the congential or acquired obstruction of the hepatic veins, also result in cardiac cirrhosis.
  16. 16.  α1-antitrypsin deficiency  Cystic fibrosis  Fructosemia  Galactosemia  Gaucher’s disease  Glycogen storage disease, type III  Glycogen storage disease, type IV
  17. 17.  Hemochromatosis  Indian childhood cirrhosis  Histiocytosis X  Niemann–Pick disease,  Tyrosinemia  Wilson’s disease  Wolman’s disease Viral hepatitides Cytomegalovirus Chronic hepatitis B +/− delta agent Chronic hepatitis C
  18. 18.  Herpes simplex virus  Rubella  Ascending cholangitis  Neonatal sepsis  Autoimmune chronic active hepatitis  Primary sclerosing cholangitis
  19. 19.  Biliary atresia  Arteriohepatic dysplasia (Alagille syndrome)  Intrahepatic biliary hypoplasia  Choledochal cyst  Congenital hepatic fibrosis  Intrahepatic cystic biliary dilatation (Caroli’s disease)
  20. 20.  Budd–Chiari syndrome  Congestive heart failure  Congestive pericarditis  Veno-occlusive liver disease  Venacaval web  Toxins found in nature (mushrooms)  Organic solvents  Hepatotoxic drugs
  21. 21.  Hypervitaminosis A  Total parenteral alimentation  Malnutrition  Cerebrohepatorenal syndrome (Zellweger’s)  Familial intrahepatic cholestasis (Byler’s disease)  Neonatal hepatitis
  22. 22. Cell injury leads to cell death (necrosis), which is followed by scar formation (fibrosis) and, in some cases, nodule formation (regeneration). Cirrhosis is the result of these three processes :  Cell injury ( extracellular matrix)  Fibrosis  Regeneration
  23. 23. The first step in the process that leads to cirrhosis is direct injury to the hepatocyte.This injury may occur as a result of almost any insult, including viral invasion, ischemia, and toxin exposure.  After injury the parenchymal cells regenerate and replace the necrotic cell . This is associated with inflammation and deposition of additional extracellular matrix (ECM), including collagen.
  24. 24. The cells responsible for intrahepatic fibrosis have not all been identified. The hepatic stellate cell is of high importance. Other cells like endothelial cell, hepatic stellate cell, kupffer cells are responsible for fibrosis. If stimulated by inflammatory cells or by various cytokines, hepatocytes and their supportive cells secrete an altered ECM. The ECM is vital to the survival and proper function of each cell; the ECM provides a stable environment within tissue compartments.
  25. 25.  In cirrhosis, the ECM is altered qualitatively and quantitatively.  In the normal liver, connective tissue proteins are seen along the basement membranes surrounding lymphatic and blood vessels, and around bile ducts. There is also scanty collagen in the perisinusoidal space. The hepatocytes and greater part of the portal triads are virtually free of connective tissue.  In cirrhosis, there are increased collagen types III and IV in the perisinusoidal space. The sinusoids are lined with a new basement membrane intimately associated with laminin and collagen type 3
  26. 26. The altered proteins (mostly synthesized by hepatocyte stellate cells) are laid down at the space of Disse, and initially there is no effect on the function of the hepatocyte. As the collagen network becomes thicker, it becomes a barrier to the intimate interface between blood and hepatocytes and interferes with exchange of substances across the hepatocyte membranes. Laminin deposition increases along sinusoids and is related to the formation of a sinusoidal basement membrane . This is so called capillarization of sinusoids.
  27. 27. The reduction in the amount of viable, well- vascularized hepatic tissue leads to compensatory growth, or nodule formation. As hepatic nodules form, they increasingly impede blood flow to the lobules by direct compression of the hepatic arterial and venous blood flow.
  29. 29.  Activation of stellate cells  Collagen deposition in space of Disse  Constriction of sinusoids  Defenestration of sinusoids Alterations in Microvasculature in Cirrhosis
  30. 30.  Although initially considered to be permanent, there is evidence suggesting that fibrosis is reversible, at least in some cases .  Some reversal of liver fibrosis has been seen in some liver diseases, such as chronic hepatitis C and nonalcoholic steatohepatitis (NASH) .
  31. 31.  Hepatic stellate cells (HSCs) are responsible for the excess production of ECM components, thus activation of HSC appears to be a key step toward the development of hepatic fibrosis. Inhibition of HSC activation has been of interest in reversing or preventing the development of hepatic fibrosis.  Such treatments include the inhibition of transforming growth factor-β (TGF-β) , platelet-derived growth factor , and herbal extracts such as silymarin.  Antioxidants such as vitamin E and silymarin protect hepatocytes from necrotic injury, inhibit hepatocyte stellate cell activation, and may result in decreased rates of fibrogenesis .
  32. 32.  Attempts are being made to treat liver fibrosis. The removal of the causative agent when possible is the first step in treating liver fibrosis and in some cases, may result in some reversal of the fibrotic process.  In general, most treatments have not been widely applied or have not been tested in adults or children and thus are not used in children with progressive liver disease.  Because inflammation is associated with the fibrotic process, anti-inflammatory medications such as corticosteroids have been used in patients with chronic liver disease.  These drugs are especially effective in treating patients with autoimmune hepatitis .
  33. 33.  In response to insult by viral invasion, cirrhosis, ischemia, trauma, or partial hepatectomy, hepatocyte proliferation increases to replace lost cells. Hepatic regeneration is a com- plex process, highly regulated at the cellular level in an autocrine or paracrine manner by cytokines, some of which themselves are regulated by prostaglandins or by other cytokines.
  34. 34.  Many hormones are known to influence the process of hepatic regeneration, including insulin, glucagon, growth hormone, adrenocorticotropic hormone (ACTH), vasopressin, cortisol, thyroxin, and estrogen.  All of these can promote hepatic proliferation, but none appears to be the initiator of the process. The recent isolation and identification of specific cytokine hepatic growth factors has shed light on the initiation and control of hepatocyte proliferation as well as fibrogenesis.
  35. 35. Salivary glands, Brunner’s glands Initiator of hepatic regenerative response. Stimulates hepatocyte DNA synthesis. Hepatocyte growth factor (HGF) Unknown Stimulates hepatocyte DNA synthesis Fibroblast growth factor (FGF) Endothelial cells Stimulates hepatocyte regeneration at low levels. High levels regulate epidermal growth factor EGF-induced proliferation. Cytokines Associated with Hepatic Regeneration CYTOKINE SOURCE ACTION Epidermal growth factor (EGF)
  36. 36. Interleukin-6 (IL-6) Kupffer cells Promotes hepatocyte proliferation Transforming growth factor-α (TGF-α) Macrophage, hepatocyte Promotes hepatic regeneration; also binds to EGF receptor
  37. 37. Mechanism of fibrosis and cirrhosis of the liver
  38. 38.  The clinical presentation of cirrhosis depends on the cause of the primary liver disease as well as on the pace of progression of hepatocellular failure and fibrosis. Many children and adolescents present with findings incidentally during routine physical examinations. In such patients, the cirrhosis is referred to as latent or compensated.  In others, chronic liver disease may be sudden and dramatic, such as with the onset of hematemesis, encephalopathy, ascites, or infection. If the signs and symptoms of cirrhosis are apparent and progressive, the term decompensated or active cirrhosis applies
  39. 39. The common mode of presentation include :  Failure to thrive  Anorexia , nausea , vomiting  Prolonged or recurrent jaundice  Pruritis  Pain abdomen ( Colicky type)  Abdominal distension  Oedema  Features of portal hypertension ( hementemesis , malena, epitaxis.)  Fever is generally presented in decompensated liver disease.
  40. 40. Other points in history • Fever, prodrome (anorexia ,vomiting ,nausea) –which disappears with onset of jaundice – acute viral hepatitis • jaundice • Young individual with extrapyramidal symptoms, neuropsychiatric manifestation, anemia • Colicky abdomen pain, jaundice, fever - gall stones • Drug history ( acetoaminophen toxicity)
  41. 41. Cholestatic disease • fatigue, malaise • anorexia, nausea • Biliary colic • Deep jaundice • +++ pruritus • +++ abdominal pain and pancreatitis • +++ gray or clay-colored stools
  42. 42. CIRRHOSIS • Fatigue • Muscle wasting • Hematemesis • Ascites • Easy bruising • Edema
  43. 43. General Poor growth, malnutrition, fever, muscle wasting Skin and extremities Jaundice, flushing or pallor, palmar erythema, spider angiomata, digital clubbing Abdomen Distention, caput medusa, ascites, larger tender liver or shrunken liver, large spleen, rectal varices Central nervous system Asterixis, positive Babinski’s reflex, prolonged relaxation phase of deep tendon refluxes, mental status changes
  44. 44. Miscellaneous Gynecomastia, testicular atrophy, feminization, delayed puberty
  45. 45. Gastrointestinal tract :  cirrhosis is associated with esophageal and gastric varices, which form as a consequence of portal hypertension.  Hematemesis secondary to variceal bleeding .  Bleeding from hemorrhoids, which arise from portosystemic shunting through the inferior mesenteric venous collateral system, is much less common.
  46. 46.  Chronic gastritis and peptic ulcer disease  Excess gastric acid may be secreted in response to direct gastric stimulation by histidine, the decarboxylated form of histamine. In healthy people, histidine is cleared from the circulation by the liver; with hepatic disease, serum histidine levels are elevated .  Gastroesophageal reflux is seen in cirrhosis and is caused by increased intra-abdominal pressure secondary to ascites and hepatosplenomegaly.  Diarrhea is a common manifestation of liver disease and may be a result of malabsorption, bile acid deficiency, or malnutrition.
  47. 47. pulmonary manifestation :  Development of arteriovenous shunts, which lead to cyanosis and dyspnea. Hypoxemia is seen in up to 30% of children with cirrhosis and can be severe enough to cause cyanosis .  Digital clubbing often accompanies longstanding intrapulmonary shunting  These shunts may result from increased vasodilation caused by vasoactive substances such as ferritin released from the diseased liver
  48. 48. Hematologic changes :  cirrhosis include anemia and coagulopathy.  The cause of the anemia of cirrhosis may be multifactorial and may include blood loss due to GI bleed, hemolysis secondary to hypersplenism, iron and folic acid deficiency secondary to malabsorption , anorexia, and dilution of red blood cell volume as a result of sodium and water retention .  The coagulopathy of cirrhosis also is multifactorial . A decrease in the synthesis of liver derived clotting proteins, including prothrombin and factors VII and IX, and increased consumption of clotting factors through increased fibrinolysis and disseminated intravascular coagulation (DIC) occur commonly in late, decompensated cirrhosis.
  49. 49. Cardiovascular manifestations:  cirrhosis include a high cardiac output state related to changes in systemic vascular resistance, pulmonary vascular resistance, and hepatic blood flow (portal hypertension).  The sustained increase in cardiac output results in the flushed appearance of patients with cirrhosis. Systemic hypertension is not common in cirrhosis
  50. 50. Skin manifestations : Spider angiomata and palmar erythema. Spider angiomata are easily recognizable as small, raised, dark lesions with radially distributed convoluted vascular branches. They arise because of vasoactive substances such as estradiol in the circulation of patients with cirrhosis. The presence of more than five in the body region drained by the superior vena cava is abnormal and is suggestive of cirrhosis.
  51. 51. Palmar erythema, a well-recognized sign of cirrhosis, is not specific to cirrhosis but is seen in other conditions associated with increased cardiac output or altered sex hormone metabolism . Caput medusae may also be present. This refers to prominent abdominal wall veins seen in patients with portal venous hypertension. Nail changes characterized by horizontal white bands (Muehrcke’s nails) may be seen in cirrhosis or in other conditions resulting in hypoalbuminemia.
  52. 52. Endocrine manifestations :  Failure of the liver to conjugate or metabolize hormones include diabetes mellitus, which may present as subtle hyperinsulinemia without overt signs; syndrome of inappropriate secretion of antidiuretic hormone, presenting as hyponatremia.  Gynecomastia may be caused by increased production of androstenedione and the increased conversion of estrone to estradiol .  In the mature adolescent, decreased libido, delayed puberty decreased facial hair, and impotence are caused by reduced testosterone synthesis in the liver .
  53. 53. Neurologic manifestations  Changes in consciousness include hypersomnia, reversal of sleep pattern, apathy, slowed speech, decreased spontaneous movement, and eventually coma.  Personality changes commonly seen in chronic liver disease include irritability, inability to cooperate,, and their true cause may not be understood until frank encephalopathy is present.  Intellectual deterioration with slight or gross confusion may be present. Tests of constructional apraxia such as writing difficulty or the Reitan trail-making test may be difficult to administer if the child is at too early a developmental stage.
  54. 54. Immune function cirrhosis result in increased susceptibility to bacterial and mycobacterial infections, resulting in an increased rate of pneumonia and spontaneous bacterial peritonitis (SBP).
  55. 55. Evaluation of a patient with liver dysfunction and suspected cirrhosis should focus on determining both the cause and the stage of liver disease. Serologic testing for infectious diseases should include screens for hepatitis B and C.  In appropriate clinical situations (fever in the setting of previous biliary tree surgery), bacterial cultures of blood and possibly liver tissue should be obtained.
  56. 56.  Tests for metabolic liver disease should include quantitation of the serum α1-antitrypsin level with determination of levels of protease inhibitor (“π- type”), fasting blood sugar (glycogen storage disease), urinary reducing substances (galactosemia), serum amino acids with urinary organic acids (tyrosinemia), serum iron, and iron binding capacity and ferritin (hemochromatosis), as well as the sweat chloride test (for cystic fibrosis).  The initial evaluation for Wilson’s disease should include serum copper, serum ceruloplasmin, a 24- hour urine collection for copper, and a slit-lamp ophthalmologic exam.
  57. 57.  An abdominal ultrasound examination aids in the evaluation of gallstones, choledochal cyst, and Caroli’s disease (cystic dilation of the intrahepatic biliary tree).  The anatomy and blood flow of the hepatic arterial and venous system also should be evaluated.  In infants, in whom the consideration of extrahepatic biliary atresia is paramount, a biliary scintiscan should be done.  In patients with suspected extrahepatic biliary tree obstruction, ERCP may be considered. The timing of liver biopsy in the investigtion of suspected cirrhosis in children remains a matter of clinical judgment.  A biopsy may be critical to confirm the presence of cirrhosis suspected on clinical grounds, or if the investigations outlined here fail to reveal the caus of the chronic liver disease
  59. 59. Hepatocellular • AST/ALT >> ALP • Unconjugated bil >> conjugated • USG – BILE DUCTS NORMAL Cholestatic • ALP>>AST/ALT • Conjugated bil>> unconjugated • ↑GGT, 5’nucleotidase • USG- Intrahepatic biliary duct dilation
  60. 60. Non hepatic cause of elevated transaminases • Muscle disease • Thyroid diseases • Bone disease - ALP
  61. 61. Diagnostic Tests in Chronic Liver Disease and Cirrhosis Disorder Diagnostic Test HBV HBsAg, E antigen/antibody, HBV DNA HCV HCV antibody, HCV RNA CMV CMV serology, urine for CMV antigen EBV EBV serology, heterophile Bacterial cholangitis Blood and liver tissue culture Autoimmune chronic active hepatitis Sedimentation rate, ANA, anti–smooth muscle antibody, antimitochondrial antibody, anti–liver-kidney-microsomal antibody
  62. 62. α1-antitrypsin deficiency Serum α1-antitrypsin level, Pi type Glycogen storage disease Lactic acid, fasting blood sugar, uric acid, liver and muscle tissue enzyme level Galactosemia Urinary non–glucose reducing sugar, red blood cell galactose-1-phosphate uridyl transferase level Tyrosinemia Serum amino acid levels, urine organic acids Hemochromatosis Serum iron TIBC, ferritin
  63. 63. Cystic fibrosis sweat chloride test, genotype analysis Toxic ingestion Toxic screen, serum acetaminophen level Wilson’s disease Serum copper, serum ceruloplasmin, 24-hour urinary collection for copper, slit-lamp exam, liver copper concentration
  64. 64. Liver Function Tests: Normal Values & Changes Tests Normal Values Hepatocellular Jaundice Uncomplicated Obstructive Jaundice Bilirubin Direct Indirect 0.1-0.3 mg/dL 0.2-0.7 mg/dL Increased Increased Increased Increased Urine bilirubin None Increased Increased Serum albumin/ total protein Alb, 3.5-5.5 g/dL Tot, 6.5-8.4 g/dL Albumin decreased Unchanged Alk phos 30-115 IU/L Increased (+) Increased (++++) Prothrombin time INR of 1.0-1.4; 10% inc. after vit K in 24 hrs No response to parenteral vit. K; prolonged Prolonged but responds to parenteral vit. K ALT, AST ALT: 5-35 IU/L AST: 5-40 IU/L Inc. in hepato- cellular damage, viral hepatitis Minimally increased
  65. 65. Differential Diagnosis of Hereditary Jaundice with Normal Liver Chemistries & No Signs or Symptoms of Liver Disease Unconjugated Hyperbilirubinemia Crigler-Najjar Syndrome Gilbert’s Type I Type II Incidence Inheritance mode Serum bilirubin usual total (mg/dL) Defect Age at onset of jaundice <7% of pop’n Very rare Uncommon AD AR AR <3; <6 >20 <20 Mostly B1; inc. All indirect All indirect with fasting Hepatic UDP-glucuronyl transferase activity Decreased Absent Marked dec. Adolescence early neonatal childhood
  66. 66. Differential Diagnosis of Hereditary Jaundice with Normal Liver Chemistries & No Signs or Symptoms of Liver Disease Unconjugated Hyperbilirubinemia Crigler-Najjar Syndrome Gilbert’s Type I Type II Usual clinical features Liver biopsy Treatment Appear in early Jaundice, Asymptomatic adulthood; kernicterus in jaundice, often 1st re- infants, kernicterus cognized w/ 1st 3day of life rare fasting Normal Normal Normal Not needed Liver transplant Phenobarbital
  67. 67. Differential Diagnosis of Hereditary Jaundice with Normal Liver Chemistries & No Signs or Symptoms of Liver Disease Conjugated Hyperbilirubinemia Dubin-Johnson Rotor’s Syndrome Incidence Inheritance mode Serum bilirubin usual total (mg/dL) Defect Urine total coproporphyrin Age at onset of jaundice Usual clinical features Oral cholecystogram Liver biopsy Treatment Uncommon AR 2-7; < 25 Direct ~ 60% Impaired biliary excretion Normal Childhood, adolescence Asymptomatic jaundice in young adults GB not visualized Charac. pigment Not needed Rare AR 2-7; < 20 Direct ~ 60% Impaired biliary excretion Increased Adolescence, early adulthood Asymptomatic jaundice Normal No pigment None
  68. 68. WILSON DISEASE • Wilson ́s disease (WD) is an autosomic recessive genetic disorder affecting gene ATP7B in chromosome 13q . It codes for trans membrane copper transporter in hepatocytes and for excretion into the bile canaliculus as well as for joining copper to ceruloplasmin. • As a result, there is an abnormal accumulation of copper in liver, brain, kidney, and other organs, mitochondrial damage, and low levels of bile copper and coeruloplasmin.
  69. 69.  Prevalence in Europe is 1/30,000, with 1/100 heterozygous. It may present as asymptomatic hypertransaminasaemia or as chronic hepatitis, cirrhosis, or acute liver failure in childhood.  In older children and adults, extrapyramidal neurological symptoms (dysarthria, dystonia, ataxia, tremor, dysphagia), psychiatric manifestations, Kayser–Fleischer ring (due to copper deposits in the Descemet corneal membrane, very specific but not pathognomonic of WD), and renal tubulopathies (with aminoaciduria and phosphaturia) are more frequent.
  70. 70. t is typical to find low plasma ceruloplasmin, although in 5–10% of patients it may be normal (>20 mg/dl), and decreased serum copper levels.  A raised urine copper after penicillamine (higher than 100 μg/day) and an elevated liver copper concentration (higher than 250 μg/g of dry liver tissue) are helpful in diagnosis. Liver biopsy shows the stage of the disease. Genetic tests (>150 mutations) may help.
  71. 71. Alpha-1-antitrypsin deficiency  In this autosomal recessive disease there is a chromosome 14 mutation that leads to the production of abnormal and hepatotoxic α1-AT that is retained in the endoplasmic reticulum . Frequency is 1:2000 newborns.  α1-AT glycoprotein may present as 100 variants, with codominant inheritance, which are classified according to the protease inhibitor (Pi) phenotype system based on their electrophoretic moiety: Pi MM variant (with normal serum concentration and normal activity), Pi null-null variant (absence of α1-AT associated with lung disease), defective variants (such as Pi Z and Pi S, with low serum concentration and lung and liver disease).
  72. 72. MM phenotype is found in healthy individuals; ZZ phenotype causes the most severe deficiency and it represents 95% of patients. SZ phenotype may cause liver disease (neonatal cholestasis, mild dysfunction, chronic hepatitis, liver failure, cirrhosis, hepatocellular carcinoma), while MS/MZ phenotypes do not produce liver disease in children but do in adults. Diagnosis is based on a decrease in the α1 band (electrophoretic gel) , a decrease in α1-AT in blood and Pi phenotype. On the liver biopsy, an abnormal accumulation of α1-AT in liver is present.
  73. 73. Nonalcoholic fatty liver disease • Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver (steatosis), nonalcoholic steatohepatitis (NASH) and cirrhosis . Most patients with NAFLD present with obesity, mainly central adiposity, as part of the metabolic syndrome21
  74. 74. The pathology of the NAFLD in children includes: Type 1, characterized by steatosis, hepatocyte balloonization, and perisinusoidal fibrosis (similar to NAFLD in adults and more frequent in white children in both sexes), and Type 2 (infantile), characterized by steatosis, portal inflammation, and portal fibrosis (more common in male and children of Asian, Native American, and Hispanic ethnicity).
  75. 75. • Clinical experience in children with NAFLD is limited. NAFLD in childhood and adolescence used to occur in the male obese patient, with AST>ALT , hypertriglyceridaemia , acanthosis nigricans . • Although most patients remain asymptomatic, other individuals may present with a variety of symptoms: hypertension, dyslipidaemia, insulin resistance, type 2 diabetes, and central obesity.
  76. 76. The gold standard test to distinguish between simple steatosis and NASH is liver biopsy. It confirms diagnosis, assesses steatosis severity, and serves as a prognostic marker. Patients with simple esteatosis have a benign course without histological progression, but patients with NAFLD may progress to cirrhosis or hepatocarcinoma .
  77. 77. PROGNOSIS Weighting Factor Variable +15 If cholesterol <100 mg/dL +15 If positive history of ascites +13 +11 If indirect bilirubin >6 mg/dL If indirect bilirubin is 3–6 mg/dL +10 If PTT is prolonged >29 seconds
  78. 78. Total score of 0–28 places patient in low-risk group (<25% risk of death within 6 months); score of 28–39 is associated with moderate- risk (25–75% risk of death within 6 months); score greater than 39 is associated with high risk (>75% of death within 6 months).